Chris Rich is a Pharma Advisor at First Ascent Biomedical. Chris has previously worked as the Senior Vice President of Wellness at GlaxoSmithKline Consumer Healthcare, where they were responsible for the introduction of OTC Flonase and oversaw the successful anti-trust negotiations with regulatory authorities around the world. Prior to that, they were on the Board of Advisors at Rocket Wagon, an Internet of Things (IoT) innovation firm.
Chris Rich received their MBA with highest honors from the Tuck School of Business at Dartmouth and their A.B. with honors in Economics/East Asian Studies from Harvard University.
Links